双特异性抗BAFF/IL-21抗体CZ105 Bis2在系统性红斑狼疮模型中的疗效
本研究构建了同时靶向IL-21和BAFF的双特异性抗体CZ105 Bis2,并在体外功能实验及多种SLE小鼠模型中评估其疗效。结果显示CZ105 Bis2的结合亲和力与细胞因子中和能力等效或优于亲本分子,且对B细胞效应功能的抑制比单独阻断BAFF或IL-21更显著,并改善狼疮样模型肾脏表现。
要点
- CZ105 Bis2同时阻断IL-21与BAFF信号通路,体外中和能力等效或优于亲本抗体。
- 在KLH模型中显著抑制T细胞依赖性抗原特异性B细胞应答。
- 在pristane诱导及人源化狼疮样模型中降低抗dsDNA抗体、减少蛋白尿及肾脏炎症浸润。
核心结论
- 临床前数据证实CZ105 Bis2在体外和体内系统中均优于单靶点生物制剂,支持其改善SLE临床结局的转化潜力。
研究设计与样本
- 制备人源化抗IL-21单克隆抗体h18B10,并将其可变域与贝利尤单抗可变域融合构建双特异性抗体CZ105 Bis2。
- 在体外功能实验及pristane诱导狼疮小鼠模型和人源化狼疮样模型(慢性移植物抗宿主病)中评估CZ105 Bis2的疗效。
主要发现
- 体外实验显示CZ105 Bis2的结合亲和力与细胞因子中和能力等效或优于两个亲本分子。
- 与选择性BAFF或IL-21抑制剂相比,CZ105 Bis2对体内B细胞效应功能产生更强抑制。
- 在钥孔戚血蓝蛋白模型中,CZ105 Bis2显著减少T细胞依赖性抗原特异性B细胞应答。
- 在pristane诱导狼疮模型和人源化狼疮样模型中,CZ105 Bis2降低抗双链DNA抗体水平、减少蛋白尿并减轻肾脏炎症浸润。
临床怎么用
- 临床前结果提示同时阻断BAFF与IL-21可能比单靶点生物制剂更有效抑制B细胞功能并改善狼疮样肾脏表现,尚需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease in which B cells play a crucial role. Although belimumab, the first B cell-targeted biologic approved for SLE, has demonstrated efficacy and tolerability, approximately 30%-40% of patients show suboptimal responses. Interleukin-21 (IL-21), a key regulator of B cell differentiation and function, is closely associated with SLE disease activity, but IL-21-targeted monotherapy has shown limited clinical efficacy. This study aimed to develop and characterize a bispecific antibody targeting both IL-21 and B cell-activating factor (BAFF) and to determine whether dual blockade provides greater therapeutic efficacy than inhibition of either pathway alone. METHODS: We prepared humanized 18B10 (h18B10), an anti-IL-21 monoclonal antibody. Building on this candidate, we constructed CZ105 Bis2, a bispecific antibody assembled by fusing the variable domains of h18B10 and belimumab, enabling concurrent blockade of IL-21 and BAFF signaling pathways. RESULTS: In vitro functional assays verified that CZ105 Bis2 exhibits binding affinity and cytokine neutralization potency equivalent or superior to its two parent molecules. Compared with selective inhibitors of BAFF or IL-21, CZ105 Bis2 elicited more robust suppression of in vivo B cell effector functions. In the keyhole limpet hemocyanin model, CZ105 Bis2 significantly reduced T cell-dependent, antigen-specific B cell responses. In both pristane-induced lupus mouse models and humanized lupus-like models (chronic graft-vs-host disease), CZ105 Bis2 decreased anti-double-stranded DNA antibody levels, reduced proteinuria, and alleviated renal inflammatory infiltration. CONCLUSION: Our preclinical data confirm that CZ105 Bis2 achieves superior efficacy over single-target biologics across in vitro and in vivo systems, supporting its translational potential to improve clinical outcomes in SLE.
引用
- Feng X, Long D, Yin H, et al. Efficacy of the Bispecific Anti-BAFF/IL-21 Antibody CZ105 Bis2 in Models of Systemic Lupus Erythematosus. Arthritis Rheumatol. 2026. PMID: 42657656. doi:10.1002/art.70310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。